Clinical Updates in Psoriatic Arthritis


The Rheumatology Network psoriatic arthritis clinical focus page provides information on the latest psoriatic arthritis news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for psoriatic arthritis drugs.

Risankizumab Receives FDA Approval for Active Psoriatic Arthritis

January 24, 2022

On Jan. 21, AbbVie announced the FDA granted approval to their IL-23 inhibitor risankizumab-rzaa (SKYRIZI) for treatment of active psoriatic arthritis in adult patients based on the results of the KEEPsAKE-1 and KEEPsAKE-2 trials.

Philip Mease, MD: Guselkumab Achieves Long-term Improvements in Psoriatic Arthritis Symptoms

December 01, 2021

Philip Mease, MD, explains the recent Phase 3 data from the DISCOVER-1 and DISCOVER-2 clinical trials which demonstrated guselkumab inhibited radiographic progression, and improved symptoms and pain in patients with active psoriatic arthritis (PsA).